Mannheimia Haemolytica Vaccine

Bovine respiratory disease causes significant economic losses in both beef and dairy calf industries. Although multi-factorial in nature, the disease is characterized by an acute fibrinous lobar pneumonia typically associated with the isolation of Mannheimia haemolytica. M. haemolytica A1 and A6 are the two most commonly isolated serotypes from cattle, however, the majority of vaccines have not demonstrated cross-serotype protection. In the current study, the efficacy of a novel, attenuated live vaccine, containing both M.

haemolytica serotype A1 and Pasteurella multocida, was evaluated in calves challenged with M. haemolytica serotype A6. Although the challenge was more severe than expected, vaccinated calves had reduced clinical scores, lower mortality, and significantly lower lung lesion scores compared to the placebo-vaccinated control group. The results demonstrate that vaccination with an attenuated live vaccine containing M. haemolytica serotype A1 can protect calves against clinical disease following challenge with M. haemolytica serotype A6.

Description

Pneumonia has always been a concern for dairy producers and Mannheimia haemolytica (M. haemolytica, formerly called Pasteurella haemolytica) is the most common cause of bacterial pneumonia in cattle.1 Exposure to respiratory viruses, coupled with reduced immunity caused by overcrowding, new herd additions, transportation, ventilation insufficiencies and sudden weather changes are factors that increase the risk of this type of pneumonia. Because these opportunistic bacteria can become deadly respiratory pathogens, more and more producers are vaccinating against this potentially devastating disease.

“Frequently, if an M. haemolytica vaccine is utilized in an adult dairy herd respiratory protocol, it is often placed in the dry period due to fear of milk loss if given during lactation,” says Dr. Brian Miller, Professional Services Veterinarian with Boehringer Ingelheim Vetmedica Inc. “However, incorporation in the dry period can be problematic due to the number of gram-negative vaccines already in place during this timeframe and concerns with endotoxin stacking (i.e., more than two gram-negative vaccines given at one time) causing a potential for anaphylaxis and abortion.

Features of Mannheimia Haemolytica Vaccine

Killed bacterin for vaccination of healthy sheep, goats and cattle as an aid in the prevention of Pasteurellosis caused by Mannheimia haemolytica and Pasteurella multocida.
Dosage: 2 ml subcut, repeat in 14-28 days. Animals vaccinated under 3 months of age should be revaccinated at 4-6 months. 21 day slaughter withdrawal.
Anaphylactoid reactions may occur. Antidote : Epinephrine.

Prices of Mannheimia Haemolytica Vaccine

$7.88 – $31.46

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.